In this article, we will list the 5 Unstoppable Stocks That Could Double Your Money. Please visit 10 Unstoppable Stocks That Could Double Your Money to see the extended list and the methodology behind it.

5. XWELL Inc. (NASDAQ:XWEL)

XWELL Inc. (NASDAQ:XWEL) is one of the unstoppable stocks that could double your money. On April 1, XWELL announced financial results for the full year 2025, reporting total revenue of ~$29.2 million. The company showed increased operational efficiency, with total operating expenses decreasing by 10% and G&A costs dropping by 20% year-over-year. While the company reported an operating loss of ~$15.7 million, it significantly supported its liquidity post-fiscal year-end through a $31.3 million private placement intended to fund debt repurchases, stock redemptions, and general corporate needs.

Throughout 2025 and early 2026, XWELL focused on diversifying its wellness services beyond traditional airport locations. Notable expansions included the opening of a tech-forward wellness center in New York City’s Penn Station and new locations in Florida markets like Brandon and Waterford Lakes. These efforts were complemented by high-profile community engagements, such as a multiyear partnership naming XWELL the official wellness spa of the Orlando Magic.

The company also continues to expand its global biosecurity footprint through its XpresCheck segment. In early 2026, XWELL Inc. (NASDAQ:XWEL) entered a partnership with PieQ to develop an AI-driven biosecurity forecasting platform for the CDC and appointed Dr. Cindy Friedman, a former CDC senior advisor, to guide its international surveillance initiatives. These developments build on a 3-year extension of the Traveler-based Genomic Surveillance program secured in 2025, as the company seeks to apply its pathogen detection models to global travel hubs and major international mass gathering events.

XWELL Inc. (NASDAQ:XWEL) is a diagnostics & research company that provides health & wellness services to travelers in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The company was known as XpresSpa Group until October 2022.

4. Cyclerion Therapeutics Inc. (NASDAQ:CYCN)

Cyclerion Therapeutics Inc. (NASDAQ:CYCN) is one of the unstoppable stocks that could double your money. On April 1, Cyclerion and Korsana Biosciences entered into a definitive merger agreement to form a combined entity operating under the name Korsana Biosciences, trading under the ticker ‘KRSA’. The merger aims to advance Korsana’s neurodegenerative disease pipeline, headlined by KRSA-028, a next-gen antibody targeting amyloid beta for Alzheimer’s disease.

This lead program uses the proprietary THETA platform, which is designed to improve brain delivery and safety while offering the convenience of subcutaneous administration. In conjunction with the merger, Korsana secured $380 million in private financing from a syndicate of leading healthcare investors, including Fairmount and Venrock Healthcare Capital Partners. This capital is expected to fund operations into 2029, providing the necessary runway to reach critical clinical milestones.

Key upcoming data readouts include Phase 1 healthy volunteer results in mid-2027 and interim proof-of-concept data regarding amyloid plaque clearance in Alzheimer’s patients by the end of 2027. The transaction follows a review by Cyclerion Therapeutics Inc. (NASDAQ:CYCN) and represents an opportunity to use Korsana’s innovative platform, which was developed in partnership with Paragon Therapeutics.

Cyclerion Therapeutics Inc. (NASDAQ:CYCN) is a biotech company that deals with serious diseases with novel sGC stimulators in the CNS and the periphery. The company is licensed by Akebia to develop Praliciguat and related products, including medical affairs.

3. Eledon Pharmaceuticals Inc. (NASDAQ:ELDN)

Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the unstoppable stocks that could double your money. On March 19, Eledon reported its financial results for the full year 2025, highlighting the clinical advancement of its anti-CD40L antibody, tegoprubart. The company announced that tegoprubart received FDA Orphan Drug designation for preventing allograft rejection in liver transplantation, adding to its existing designations for pancreatic islet cell transplantation and ALS.

Clinical data from a Phase 1b long-term extension study in kidney transplantation showed a favorable safety profile over 24 months, with no reported graft losses or rejection episodes and an improvement in mean estimated glomerular filtration rate. In a University of Chicago Medicine-led study, tegoprubart showed promising results in treating type 1 diabetes via islet transplantation. For 2026, Eledon anticipates receiving FDA guidance for a Phase 3 trial in kidney transplantation and plans to initiate new investigator-led studies in liver and islet cell transplantation.

Financial results for 2025 reflected increased investment in clinical programs, with R&D expenses rising to $66.3 million from $52 million in the previous year. This increase was driven by expanded trial activities, manufacturing scale-up, and additional personnel. Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) reported a net loss of $45.6 million for the year, which included a $33.4 million non-cash gain from changes in the fair value of warrant liabilities.

Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is a clinical-stage biotechnology company that targets the CD40L pathway to develop ALS treatments and therapies to prevent organ transplant rejection. The company’s lead candidate, tegoprubart, is an anti-CD40L IgG1 antibody.

2. Edesa Biotech Inc. (NASDAQ:EDSA)

Edesa Biotech Inc. (NASDAQ:EDSA) is one of the unstoppable stocks that could double your money. On March 26, Edesa reaffirmed that enrollment for its Phase 2 clinical study of EB06, which is a treatment for moderate-to-severe nonsegmental vitiligo, is on track to begin in mid-2026. The company has selected JSS Medical Research as its clinical research organization and has initiated outreach to potential clinical sites. Recruitment is expected to start at investigational sites in Canada, following the approval of the company’s clinical trial application.

The upcoming study will evaluate the safety and efficacy of EB06, a monoclonal antibody designed to target the chemokine CXCL10, which plays a critical role in the destruction of skin pigment cells. By neutralizing this protein, EB06 aims to prevent and reverse the depigmentation associated with vitiligo. The CEO emphasized that the trial design has been refined through discussions with key opinion leaders to address the significant need for effective systemic therapeutics in a market with few approved options.

EB06 has already shown biological activity and a favorable safety profile in three previous clinical studies involving 65 subjects. While the current Phase 2 trial will use an intravenous formulation, Edesa Biotech Inc. (NASDAQ:EDSA) is also developing a subcutaneous version for future clinical evaluation.

Edesa Biotech Inc. (NASDAQ:EDSA) is a clinical-stage biotech company that was founded in 2015. The company researches, develops, manufactures, and commercializes products for inflammatory and immune-related diseases.

1. TuHURA Biosciences Inc. (NASDAQ:HURA)

TuHURA Biosciences Inc. (NASDAQ:HURA) is one of the unstoppable stocks that could double your money. TuHURA announced its financial results for Q4 and the full year. The company is advancing its Phase 3 trial for IFx-2.0 as an adjunctive treatment for Merkel Cell Carcinoma/MCC under an FDA Special Protocol Assessment, with enrollment expected to conclude in mid-2027. To support its development pipeline, TuHURA acquired Kineta’s VISTA-inhibiting antibody, TBS-2025, for $10.5 million and appointed Dr. Craig Tendler to provide oversight for clinical operations.

Significant corporate milestones include the initiation of a Phase 1b/2a study for IFx-2.0 in patients with metastatic MCC of unknown primary origin and the presentation of data at ASH identifying the Delta Opioid Receptor as a target for overcoming immunotherapy resistance. For 2026, the company expects to receive Orphan Drug Designation for IFx-2.0 in MCC and plans to meet with the FDA regarding TBS-2025’s development in AML. Additionally, TuHURA aims to select its lead antibody-drug conjugate and initiate proof-of-concept studies within the second half of the year.

TuHURA Biosciences Inc. (NASDAQ:HURA) reported $3.6 million in cash and cash equivalents at the end of 2025, supplemented by $7.5 million received in early 2026. Annual R&D expenses rose to $20.5 million, reflecting increased investment in its clinical programs compared to the previous year. The company successfully raised $21.2 million through private placements and offerings during this period, supporting its ongoing efforts to develop novel immuno-oncology therapeutics.

TuHURA Biosciences Inc. (NASDAQ:HURA) is a clinical-stage biotech firm that develops novel immuno-oncology technologies for cancer treatment. The company was formerly known as Morphogenesis until December 2023.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.